Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 137

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 131 132 133 134 135 136 < 137 > 138 139 140 141 142 143 .. 184 >> Следующая

122. George J, Harats D, Gilburd B, et al. Adoptive transfer of 2-glycoprotein I-reactive lymphocytes enhanced early atherosclerosis in LDL receptor deficient mice. Circulation 2000; 102: 1822—1827.
123. George J, Harats D, Gilburd B, et al. Immunolocalisation of 2-glycoprotein I (apoli-poprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999; 99: 2227—2230.
SHS-OOO4.qxd 21.11.2006 16:56 Page 3 3/4"
34
Насонов Е.Л. Антифосфолипидный синдром.
124. Harats D, George J. ?2-glycoprotein I and atherosclerosis. Curr Opin Lipidol; 2001; 12: 543—546.
125. Aho K, Vaarala O, Tenkanen L, et al. Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 499—506.
126. Amengual O, Atsumi T, Khamashta MA, et al. Antibodies against oxidized low-density lipoprotein(ox-LDL) in 107 patients with antiphospholipid syndrome.(APS). Arthritis Rheum 1996; 39 (Suppl.): 96.
127. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923—925.
128. Vaarala O, Puurunen M, Lukka M, et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidised low-density lipoprotein. Clin Exp Immunol 1996; 104: 269—274.
129. Насонов ЕЛ, Попкова ТВ, Ефремов ЕЕ, и соавт. Антитела к окисленному липопро-теину низкой плотности при системной красной волчанке: связь с антителами к фос-фолипидам. Клин. медицина, 1997; 9: 49—52.
130. Romero FI, Amengual O, Atsumi T, et al. Arterial disease in lupus and secondary antiphos-pholipid syndrome: association with anti-?2 gly-coprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br J Rheumatol 1998; 37: 883—888.
131. Horkko S, Miller E, Dudl E, et al. Anti-phospholipid antibodies are directed against epi-topes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to oxidized low density lipoprotein. J Clin Invest 1996; 98: 818—823.
132. Horkko S, Olee T, Mo L, et al. Anticar-diolipin antibodies from patients with the antiphosphlipid antibody syndrome recognize epitope in both ?2-glycoprotein I and oxidized low density lipoprotein Circulation 2001; 103: 941— 946.
133. Mizutani H, Kurata Y, Kosugi S, et al. Monoclonal anticardiolipin autoantibodies estab-
lished from the (New Zeland WhiteXBXSB)F1 mouse model of antiphospholipid syndrome cross-rea^ with oxidized low-density lipoprotein. Arthritis Rheum. 1995; 38: 1382—1388.
134. Matsuura E, Kobayashi K, Kasahara J, et al. Oxidized autoantigens in atherosclerosis. In. Atherosclerosis and autoimmunity Ed. Y Schoenfeld, D. Harats, G Wick. Elsevier 2001; 143—150.
135. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized low density lipoproteins forms complexes with ?2-glycoprotein I: implications as an atherogenic autoantigen. JLR 2003; M200329—LR200.
136. Arfos L, Lefvert AK. Enrichment of antibodies against phospholipid in circulating immune complex (CIC) in the anti-phospholipid syndrome (APLS), Clin Exp Imunol 1997; 108: 47—51.
137. Wu R, Huang YH, ElinderLS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Ather Thromb Vasc Biol 1998; 18: 626—630.
138. Wu R, Svennungsson E, Gunnatsson I, etal. Antibodies against lysophosphatidylcholin and oxidase LDL in patients with SLE. Lupus 1999; 8: 142—150.
139. Elinder LS, Dumitresku A, Larson P, et al. Expression of phospholipasa A2 isoforms in human normal and atherosclerotic arterial wall. Arter Thromb Vasc Biol 1997; 17: 2257— 2263.
140. Pruzanski W, Goulding NJ, Flower RJ, et al. Circulating group II phospholipasa A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol 1994; 21: 252—257.
141. Forte TM, McCall MR. The role of apolipoprotein Al-contaning lipoproteins in atherogenesis. Curr Opin Lipidol 1994; 5: 354— 364.
142. Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of Interleukin-1 bets and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 2381—2389.
143. Merril JT, Weinstein A, Dinu A, et al. Antibodies to apolipoprotein A1 in lupus population: cross-reactivity with anti-beta2 glycopro-
SHS-OOO4.qxd 21.11.2006 16:56 Page 3 3/8
35
.ГЛАВА 12. Атеросклеротическое поражение сосудов при системной красной волчанке и АФС
tein-1. Arthritis Rheum 1996; 39 (Suppl): 93 (abst).
144. Dinu AR, Merrill JT, Shen C, et al. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998; 7: 355—380.
145. Abe H, Tsuboi N, Suzuki S, et al. Anti-apolipoprotein A-I antibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatology 2001; 28: 990—995.
Предыдущая << 1 .. 131 132 133 134 135 136 < 137 > 138 139 140 141 142 143 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed